Patents by Inventor Frank Ivy Carroll
Frank Ivy Carroll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11292783Abstract: Potent opioid receptor antagonists of formula (I) and their use as pharmacotherapies for treating depression, anxiety, schizophrenia, eating disorders, and addiction to cocaine, methamphetamine, nicotine, alcohol, and opiates are disclosed. More specifically, the disclosure provides potent and selective kappa opioid receptor antagonist compounds, pharmaceutical compositions of those compounds and uses of those compounds to ameliorate or treat addictions, eating disorders, etc.Type: GrantFiled: September 15, 2017Date of Patent: April 5, 2022Assignee: Research Triangle InstituteInventors: Frank Ivy Carroll, Chad M. Kormos, Pauline W. Ondachi, Scott P. Runyon, Hernan A. Navarro, James B. Thomas, S. Wayne Mascarella
-
Patent number: 10919841Abstract: The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.Type: GrantFiled: December 22, 2016Date of Patent: February 16, 2021Assignee: Research Triangle InstituteInventors: Frank Ivy Carroll, Bruce Edward Blough, Philip Abraham
-
Publication number: 20190263781Abstract: Potent opioid receptor antagonists of formula (I) and their use as pharmacotherapies for treating depression, anxiety, schizophrenia, eating disorders, and addiction to cocaine, methamphetamine, nicotine, alcohol, and opiates are disclosed. More specifically, the disclosure provides potent and selective kappa opioid receptor antagonist compounds, pharmaceutical compositions of those compounds and uses of those compounds to ameliorate or treat addictions, eating disorders, etc.Type: ApplicationFiled: September 15, 2017Publication date: August 29, 2019Applicant: Research Triangle InstituteInventors: Frank Ivy Carroll, Chad M. Kormos, Pauline W. Ondachi, Scott P. Runyon, Hernan A. Navarro, James B. Thomas, S. Wayne Mascarella
-
Publication number: 20180215701Abstract: The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.Type: ApplicationFiled: December 22, 2016Publication date: August 2, 2018Inventors: Frank Ivy Carroll, Bruce Edward Blough, Philip Abraham
-
Patent number: 9750738Abstract: Provided are opioid receptor antagonists represented by the formula (I): where R, Y3, R1, R2, R3, R4 and R5 are as defined herein.Type: GrantFiled: December 14, 2015Date of Patent: September 5, 2017Assignee: RESEARCH TRIANGLE INSTITUTEInventors: Frank Ivy Carroll, Juan P. Cueva, James B. Thomas, S. Wayne Mascarella, Scott P. Runyon
-
Patent number: 9562001Abstract: The invention provides bupropion analog compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.Type: GrantFiled: October 12, 2011Date of Patent: February 7, 2017Assignee: Research Triangle InstituteInventors: Frank Ivy Carroll, Bruce Edward Blough, Philip Abraham
-
Patent number: 9527823Abstract: The invention provides hydroxybupropion analogs capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and/or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity.Type: GrantFiled: November 10, 2014Date of Patent: December 27, 2016Assignees: Research Triangle Institute, Dignity Health, Virginia Commonwealth UniversityInventors: Frank Ivy Carroll, Bruce E. Blough, Hernan A. Navarro, S. Wayne Mascarella, Ana Zamfira Muresan, M. Imad Damaj, Ronald J. Lukas
-
Patent number: 9303092Abstract: The invention generally relates to hapten compounds comprising either (+) methamphetamine or (+) amphetamine conjugated to a linker. Generally speaking, hapten compounds of the invention may be used to elicit an immune response to one or more of (+) methamphetamine, (+) amphetamine, or (+) MDMA.Type: GrantFiled: September 7, 2012Date of Patent: April 5, 2016Assignee: The Board of Trustees of the University of ArkansasInventors: Samuel M. Owens, Frank Ivy Carroll, Philip Abraham
-
Patent number: 9284322Abstract: Provided herein are compounds and methods of preparation of compounds that are capable of functioning as agonists or antagonists of a nicotinic receptor. Also provided are pharmaceutical compositions comprising one or more of these compounds, which may further comprise one or more additional therapeutic agents. Further provided are methods of treatment of various conditions that may be responsive to such activity at the nicotinic receptors, such as nicotine dependence.Type: GrantFiled: February 6, 2015Date of Patent: March 15, 2016Assignee: Research Triangle InstituteInventors: Frank Ivy Carroll, Pauline Wanjiku Ondachi
-
Publication number: 20150307502Abstract: Compounds and compositions for promoting smoking cessation or decreasing tobacco use or nicotine addiction are provided. The compounds are 2?-fluoro-3?-(substituted phenyl) deschloroepibatidine analogs. The compounds have been found to modulate neuronal nicotine acetylcholine receptors and are useful in methods for the treatment of conditions or disorders influenced by the modulation of neuronal nicotinic acetylcholine receptors.Type: ApplicationFiled: December 26, 2012Publication date: October 29, 2015Inventors: Frank Ivy Carroll, Pauline Wanjiku Ondachi, Hernan A. Navarro, M. Imad Damaj, James H. Woods, Emily M. Jutkiewicz
-
Patent number: 9150581Abstract: Compounds and compositions for promoting smoking cessation or decreasing tobacco use or nicotine addiction are provided. The compounds are 2?-fluoro-3?-(substituted phenyl) deschloroepibatidine analogs. The compounds have been found to modulate neuronal nicotine acetylcholine receptors and are useful in methods for the treatment of conditions or disorders influenced by the modulation of neuronal nicotinic acetylcholine receptors.Type: GrantFiled: December 26, 2012Date of Patent: October 6, 2015Assignees: RESEARCH TRIANGLE INSTITUTE, THE REGENTS OF THE UNIVERSITY OF MICHIGAN, VIRGINIA COMMONWEALTH UNIVERSITYInventors: Frank Ivy Carroll, Pauline Wanjiku Ondachi, Hernan A. Navarro, M. Imad Damaj, James H. Woods, Emily M. Jutkiewicz
-
Publication number: 20150152119Abstract: Provided herein are compounds and methods of preparation of compounds that are capable of functioning as agonists or antagonists of a nicotinic receptor. Also provided are pharmaceutical compositions comprising one or more of these compounds, which may further comprise one or more additional therapeutic agents. Further provided are methods of treatment of various conditions that may be responsive to such activity at the nicotinic receptors, such as nicotine dependence.Type: ApplicationFiled: February 6, 2015Publication date: June 4, 2015Inventors: Frank Ivy Carroll, Pauline Wanjiku Ondachi
-
Publication number: 20150141416Abstract: The invention provides hydroxybupropion analogues capable of inhibiting the reuptake of one or more monoamines and/or acting as antagonists at nicotinic acetylcholine receptors. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin and/or may selectively bind to one or more nicotinic acetylcholine receptor subtypes. Such compounds may be used to treat conditions that are responsive to modification of monoamine levels and/or antagonism of nicotinic acetylcholine receptors, including drug dependency, depression, and obesity.Type: ApplicationFiled: November 10, 2014Publication date: May 21, 2015Inventors: Frank Ivy Carroll, Bruce E. Blough, Hernan A. Navarro, S. Wayne Mascarella, Ana Zamfira Muresan, M. Imad Damaj, Ronald J. Lukas
-
Patent number: 8981102Abstract: Provided herein are compounds and methods of preparation of compounds that are capable of functioning as agonists or antagonists of a nicotinic receptor. Also provided are pharmaceutical compositions comprising one or more of these compounds, which may further comprise one or more additional therapeutic agents. Further provided are methods of treatment of various conditions that may be responsive to such activity at the nicotinic receptors, such as nicotine dependence.Type: GrantFiled: August 19, 2011Date of Patent: March 17, 2015Assignee: Research Triangle InstituteInventors: Frank Ivy Carroll, Pauline Wanjiku Ondachi
-
Publication number: 20140357674Abstract: Compounds and compositions for promoting smoking cessation or decreasing tobacco use or nicotine addiction are provided. The compounds are 2?-fluoro-3?-(substituted phenyl) deschloroepibatidine analogs. The compounds have been found to modulate neuronal nicotine acetylcholine receptors and are useful in methods for the treatment of conditions or disorders influenced by the modulation of neuronal nicotinic acetylcholine receptors.Type: ApplicationFiled: December 26, 2012Publication date: December 4, 2014Inventors: Frank Ivy Carroll, Pauline Wanjiku Ondachi, Hernan A. Navarro, M. Imad Damaj, James H. Woods, Emily M. Jutkiewicz
-
Publication number: 20130296537Abstract: The invention generally relates to hapten compounds comprising either (+) methamphetamine or (+) amphetamine conjugated to a linker. Generally speaking, hapten compounds of the invention may be used to elicit an immune response to one or more of (+) methamphetamine, (+) amphetamine, or (+) MDMA.Type: ApplicationFiled: September 7, 2012Publication date: November 7, 2013Applicant: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSASInventors: Samuel M. Owens, Frank Ivy Carroll, Philip Abraham
-
Publication number: 20130158072Abstract: Kappa opioid recep-tor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor, such as heroin or cocaine addictions.Type: ApplicationFiled: January 19, 2010Publication date: June 20, 2013Applicant: Research Triangle InstituteInventors: Frank Ivy Carroll, James B. Thomas, S. Wayne Mascarella
-
Publication number: 20130150373Abstract: Provided herein are compounds and methods of preparation of compounds that are capable of functioning as agonists or antagonists of a nicotinic receptor. Also provided are pharmaceutical compositions comprising one or more of these compounds, which may further comprise one or more additional therapeutic agents. Further provided are methods of treatment of various conditions that may be responsive to such activity at the nicotinic receptors, such as nicotine dependence.Type: ApplicationFiled: August 19, 2011Publication date: June 13, 2013Applicant: Research Triangle InstituteInventors: Frank Ivy Carroll, Pauline Wanjiku Ondachi
-
Patent number: 8299222Abstract: The invention generally relates to hapten compounds comprising either (+) methamphetamine or (+) amphetamine conjugated to a linker. Generally speaking, hapten compounds of the invention may be used to elicit an immune response to one or more of (+) methamphetamine, (+) amphetamine, or (+) MDMA.Type: GrantFiled: November 3, 2009Date of Patent: October 30, 2012Assignee: The Board of Trustees of the University of ArkansasInventors: Samuel M. Owens, Frank Ivy Carroll, Philip Abraham
-
Publication number: 20120178781Abstract: Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.Type: ApplicationFiled: February 29, 2012Publication date: July 12, 2012Applicant: RESEARCH TRIANGLE INSTITUTEInventors: Frank Ivy CARROLL, Hernan A. Navarro, Lawrence E. Brieaddy, Scott P. Runyon, James B. Thomas